MedTrace Logo

An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD

NCT00302380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2011-06-28

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the Binding Potential in subjects with ADHD and adults without ADHD: the intent being to demonstrate that C-11 Altropane PET can be used to differentiate adults with ADHD from healthy control subjects.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

RADIATION

PET imaging using C-11 altropane as the ligand.

A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Thomas Spencer, MD · Massachusetts General Hospital

Eligibility

Min Age
18 Months
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2006-03-31
Completion
2006-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302380 on ClinicalTrials.gov